Marie-Eve Beaulieu

Marie-Eve Beaulieu is a prominent figure in the biotechnology industry, serving as the Co-founder, Chief Scientific Officer, and Board member at Peptomyc.23 Her background is rooted in scientific research, particularly in the field of pharmacology.

Education and Research

Dr. Beaulieu holds a PhD in Pharmacology from the Université de Sherbrooke, which she completed in 2011.1 During her doctoral studies, she worked under the supervision of Dr. Pierre Lavigne, focusing on the structural biology of c-Myc and Max proteins.1 This research likely laid the foundation for her future work in targeted cancer therapies.

Professional Career

At Peptomyc, Marie-Eve Beaulieu plays a crucial role in driving the company's scientific direction and strategy. As the Chief Scientific Officer, she is responsible for overseeing the research and development efforts of the company.2 Her position as a co-founder and board member also suggests that she has been instrumental in shaping the company's vision and growth from its inception.3

Expertise and Contributions

Dr. Beaulieu's expertise extends beyond her scientific knowledge. She is recognized as:

• A Senior Business Developer
• An Innovation Leader
• An Investment Pitch Expert
• A Status Quo Challenger4

These roles highlight her ability to bridge the gap between scientific research and business development, which is crucial for a biotechnology startup.

Advocacy and Leadership

Marie-Eve Beaulieu is also actively involved in promoting women in science and supporting gender equality in the field.24 Her participation in events like the International Day of Women and Girls in Science demonstrates her commitment to inspiring and empowering future generations of female scientists.

Through her work at Peptomyc and her various roles, Marie-Eve Beaulieu continues to make significant contributions to the field of cancer research and biotechnology, while also advocating for important causes within the scientific community.